

Pharmacy and Therapeutics Committee

February 19, 2025



Prayer



Approval of Minutes



FMOLHS System P&T Committee

Policy and SOPs



FMOLHS System P&T Recommendations:

- System P&T Committee Policy [FMOLHS System PT Policy and Procedures 2024 Revision 12 18 24.doc](#)
- SOP_Formulary Additions [SOP Formulary Additions to System PT Final.docx](#)
- SOP_Local versus System P&T Functions [SOP Local Pharmacy & Therapeutics.docx](#)



FMOLHS System P&T Committee

Class Reviews



FMOLHS System P&T Recommendations:

Tetracyclines – UPDATE

- AMS recommendations - add tetracycline to formulary with restriction for treating *H. pylori* only.
- It is part of bismuth quadruple therapy which is now a guideline recommended first-line treatment option for *H. pylori*.

https://gi.org/journals-publications/ebgi/schoenfeld_sep2024/

TETRACYCLINES	
Doxycycline, minocycline (PO)	FORMULARY
Tetracycline	FORMULARY – <i>restricted to H.pylori tx</i>
Tigecycline & eravacycline	FORMULARY - <i>restricted to infectious disease</i>
Demeclocycline, doxycycline ER, minocycline ER, Minocycline (IV), omadacycline, sarecycline	NON-FORMULARY



FMOLHS System P&T Recommendations:

Anti Hemorrhagic Agents – UPDATE / Anticoagulant Reversal Class Review

- Given the increased risk of thrombotic events without evidence of a clinical benefit that outweighs this risk, FDA rejection of full approval, and increased cost compared to the current formulary agent, 4 factor – PCC, we do not recommend addition of andexanet alfa to system formulary.

ANTIHEMORRHAGIC AGENTS - UPDATE	
Andexanet alfa	NON-FORMULARY



FMOLHS System P&T Recommendations:

ANTIDOTES FOR ANTICOAGULANTS

Phytonadione/Vitamin K and protamine sulfate	FORMULARY
--	-----------

ANTIDOTE/MUCOLYTIC AGENT

Acetylcysteine	FORMULARY
----------------	-----------

NEUROKININ-1 RECEPTOR ANTAGONIST, parts 1 & 2

Aprepitant, Fosaprepitant (Emend)	FORMULARY – <i>restricted to use by medical oncologists for the prevention of acute and delayed emesis for moderately or highly emetogenic chemotherapy</i>
-----------------------------------	---

Aprepitant (Cinvanti)	FORMULARY – <i>restricted to use in the outpatient setting by Hem/Onc only</i>
-----------------------	--

Aprepitant (Aponvie), Fosaprepitant (Focinvez), rolapitant (Varubi), netupitant/palonosetron (Akynzeo PO), Fosnetupitant/palonosetron (Akynzeo IV)	NON-FORMULARY
--	---------------



FMOLHS System P&T Committee

*Consent Agenda Class Review
Recommendations Summary*



FMOLHS System P&T Recommendations:

FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE	
Balfaxar® (prothrombin complex concentrate, human)	FORMULARY
Kcentra® (prothrombin complex concentrate, human)	NON-FORMULARY

5-HT3 RECEPTOR ANTAGONISTS	
Ondansetron	FORMULARY
Palonosetron	FORMULARY - <i>outpatient oncology setting and inpatients on cisplatin therapy, stem cell transplant plans, and induction acute leukemia plans where appropriate.</i>
Granisetron	FORMULARY - <i>restricted to pediatrics who have failed ondansetron therapy.</i>
Netupitant-palonosetron fosnetupitant-palonosetron dolasetron	NON-FORMULARY



FMOLHS System P&T

Consent Agenda Class Review Recommendations Summary

ACE INHIBITORS

Lisinopril, enalapril/enalaprilat

FORMULARY

Benazepril, quinapril, ramipril, captopril,
fosinopril, moexipril, perindopril, trandolapril

NON-FORMULARY

ANGIOTENSIN RECEPTOR ANTAGONISTS

Losartan, valsartan, valsartan/sacubitril (Entresto®)

FORMULARY

Candesartan, irbesartan, olmesartan, telmisartan, azilsartan

NON-FORMULARY



FMOLHS System P&T

Consent Agenda Class Review Recommendations Summary

ANTICONVULSANTS BARBITURATES	
Phenobarbital tablets, elixir, & injection	FORMULARY
Pentobarbital, phenobarbital, primidone, methohexital Butalbital/APAP/caffeine (Fioricet)	FORMULARY
Amobarbital, Butalbital/APAP, butalbital/APAP/caffeine/codeine Fioricet/Codeine), butalbital/aspirin/caffeine (Fiorinal), & butalbital/aspirin/caffeine/codeine	NON-FORMULARY

ANTICONVULSANTS DIBENAZAPINE	
Carbamazepine immediate release tablets, ER tablets, & oral suspension Oxcarbazepine immediate release tablets & oral suspension	FORMULARY
Carbamazepine ER capsules, Carbamazepine chewable tablets Oxcarbazepine ER tablets, Eslicarbazepine	NON-FORMULARY



FMOLHS System P&T

Consent Agenda Class Review Recommendations Summary

ANTICONVULSANTS GABA	
Gabapentin capsules & oral suspension	FORMULARY
Vigabatrin	FORMULARY – <i>restricted to hospitals registered with the REMS program (Lourdes is not)</i>
Gabapentin ER, Gabapentin tablets, Tiagabine	NON-FORMULARY
ANTICONVULSANTS HYDANTOIN	
Phenytoin & Fosphenytoin	FORMULARY
ANTICONVULSANTS MISC 1	
Topiramate IR tablets & sprinkle capsules	FORMULARY
Topiramate oral solution, rufinamide	FORMULARY – <i>restricted to pediatrics</i>
Cannabidiol	FORMULARY - <i>restricted to Lennox-Gastaut & Dravet Syndromes</i>
Fenfluramine and Stiripentol	NON-FORMULARY



FMOLHS System P&T

Consent Agenda Class Review Recommendations Summary

ANTIGONADOTROPINS

Cetrorelix (Cetrotide), ganirelix (Fyremadel), degarelix (Firmagon), relugolix (Orgovyx), elagolix (Orlissa)	FORMULARY - <i>restricted to outpatient.</i>
--	--

ANTI-PARKINSONS AGENTS COMT INHIBITORS

Entacapone	FORMULARY
Opicapone, tolcapone	NON-FORMULARY

ANTI-PARKINSONS AGENTS DOPAMINE AGONISTS

Amantadine, pramipexole, ropinirole (immediate release formulations)	FORMULARY
Apomorphine, rotigotine, Amantadine, pramipexole, ropinirole (extended-release formulations)	NON-FORMULARY



FMOLHS System P&T

Consent Agenda Class Review Recommendations Summary

ANTI-PARKINSONS AGENTS MOAB INHIBITORS

Rasagiline tablets, Selegiline tablets	FORMULARY
Selegiline (ODT, patch, capsules), Safinamide	NON- FORMULARY

ANTI-PARKINSONS AGENTS MISC

Trihexyphenidyl	FORMULARY
Istradefylline	NON-FORMULARY



FMOLHS System P&T

Consent Agenda Class Review Recommendations Summary

AROMATASE INHIBITORS

Anastrozole (Arimidex), Letrozole (Femara),
Exemestane (Aromasin)

FORMULARY

Ribociclib/letrozole (Kisqali Femara Co-Pack®)

NON-FORMULARY

BONE RESORPTION INHIBITORS

Pamidronate, Zoledronic acid (Zometa®)

FORMULARY

Zoledronic acid (Reclast®), Ibandronate (Boniva®),
Denosumab (Prolia®, Xgeva®)

FORMULARY – *restricted to outpatient*

Alendronate, Risedronate

NON-FORMULARY



FMOLHS System P&T

Consent Agenda Class Review Recommendations Summary

CALCITONIN	
Calcitonin nasal spray	FORMULARY
Calcitonin IM	FORMULARY – <i>restricted to 2 doses in patients with symptomatic hypercalcemia and uncorrected calcium level of at least 13</i>
ESTROGEN RECEPTOR ANTAGONISTS/MODIFIERS	
Raloxifene (Evista®), Tamoxifen (Soltamox®)	FORMULARY
Fulvestrant (Faslodex®)	FORMULARY – <i>restricted to outpatient</i>
Toremifene (Fareston®), Elacestrant (Orserdu®)	NON-FORMULARY
OPTICAL IMAGING/DIAGNOSTIC AGENT	
Aminolevulinic Acid (Gleolan)	FORMULARY – <i>restricted to surgeons who have completed appropriate training and have appropriate equipment on site.</i>



FMOLHS System P&T

Consent Agenda Class Review Recommendations Summary

GONADOTROPIN RELEASING HORMONE (GnRH) AGONISTS, LEUPROLIDE

Leuprolide acetate (Lupron®)

FORMULARY

Leuprolide acetate (Lupron Depot®*, Lupron Depot-Ped®, Eligard®, Fensolvi®) Leuprolide mesylate (Camcevi®)

FORMULARY – *restricted to outpatient*

****Lupron Depot** will be restricted and available via the non-formulary process for patients with Prostate Cancer with spinal metastasis that require urgent treatment .*

GONADOTROPIN RELEASING HORMONE (GnRH) AGONISTS, OTHER

Triptorelin pamoate (Trelstar®, Triptodur®), goserelin acetate (Zoladex®), histrelin acetate (Supprelin LA®), naferelin acetate (Synarel®)

FORMULARY – *restricted to outpatient*



Lourdes Health P&T Committee

Measurements



ADVERSE DRUG REACTIONS - Oct Nov Dec 2024

EVENT ID	EVENT DATE	DRUG	REACTION	INTERVENTION
	10/2/2024	RBCs	transfusion reaction	
HLR19319847	10/8/2024	irinotecan	pain to chest & hips	paused infusion
WCV19328684	10/14/2024	fluorouracil	shortness of breath	NS, diphenhydramine, famotidine, methylprednisolone
	11/12/2024	RBCs	transfusion reaction	
RGW19372272	11/12/2024	ferric derisomaltose (Monoferric)	SOB, chest pain, back pain, facial flushing, nausea	famotidine, ondansetron
DQN19406533	12/6/2024	Penicillin G	seizure	divalproex, levetiracetam per neurology
JTL19427085	12/20/2024	oxaliplatin	increased cold sensitivity	diphenhydramine, hot coffee




BCMA Medication Scanning % by Quarter




Medication Events per 1000 patient days

**Acadiana market reporting together*



ACC/HH Top Occurrence Departments



WCC Top Occurrence Departments

